Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



The Relationship of Systemic Inflammatory Parameters with Mortality and Prognosis in Patients with COVID-19 and Acute Ischemic Stroke

Dilek Yılmaz Okuyan ,Meltem Karacan Gölen.




Abstract
Cited by 0 Articles

Introduction and aim: Inflammation plays a very important role in acute ischemic stroke (AIS) and various inflammatory markers are known to be associated with the prognosis of AIS. In this study, we aimed to evaluate the relationship of the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI), which are two new inflammatory markers, with mortality and prognosis in patients with COVID-19 and AIS.
Methods:Ninety-fivepatients with COVID-19 who were followed up for AIS were included in this study. SIRI and SII values were calculated using laboratory data at admission. The patients were divided into two groups according to prognosis and mortality. The modified Rankin scale (mRS) was used for prognosis at 3 months and mRS 0-2 was considered a good prognosis. Laboratory parameters neutrophil/lymphocyte ratio (NLR), SII, and SIRI values were compared between the groups according to prognosis and mortality.
Results:The NLR, SII, and SIRI values were found to be significantly higher in the poor prognosis group and the group with mortality (p

Key words: COVID-19; stroke; SII; SIRI; prognosis; mortality






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.